BACKGROUND: @entity618 ( @entity2098 ) has been shown to have promise in short-term liver transplantation graft rescue studies. The purpose of this study was to evaluate the long-term efficacy and safety of @entity2098 in liver transplant @entity1 who had failed @entity205 ( @entity870 )-based conventional immunosuppression. METHODS: Nineteen orthotopic liver allograft recipients were converted from @entity500 to @entity2098 in combination with @entity870 and @entity229 in this prospective, open-labeled, single-center, graft rescue, pilot study. Six @entity1 were taken off @entity870 when @entity2098 was initiated. A 4-year @entity1 follow-up is reported here. @entity1 were considered to have failed @entity870 -based immunosuppression either for refractory rejection, chronic rejection, or severe @entity870 @entity137 . RESULTS: Twelve @entity1 had complete histologic resolution, two had partial resolution, and three had worsening of their rejection. Thirteen @entity1 had a complete biochemical response; one had a partial response and four had worsening of their rejection. Two @entity1 had no histologic and one no biochemical follow-up. Of the six @entity1 treated with @entity2098 and @entity229 alone, four had complete resolution of rejection without recurrence. The majority of adverse reactions were gastrointestinal [nausea and/or vomiting (n=5); @entity294 (n=8); @entity3621 , @entity9317 , or @entity2910 (n=4); and @entity1066 (n=2)] or bone marrow suppressive [ @entity1431 (n=9), @entity417 (n=6), and @entity882 (n=5)]. CONCLUSIONS: @entity2098 seems to be an effective alternative immunosuppressive in @entity1 failing @entity870 -based conventional therapy. @entity2098 may be of particular benefit in @entity1 who do not tolerate @entity870 or @entity1140 . The long-term safety profile is similar to that of other immunosuppressives.

Four-year follow-up of XXXX for graft rescue in liver allograft recipients.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['neurologic toxicity'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity500 :: ('MESH:D001379', 'Chemical') :: ['azathioprine'] @entity870 :: ('CHEBI:55379', 'Chemical') :: ['CsA'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity2910 :: ('MESH:D004941', 'Disease') :: ['esophagitis'] @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcers'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine'] @entity2098 :: ('CHEBI:8764', 'Chemical') :: ['MMF'] @entity618 :: ('MESH:C063008', 'Chemical') :: ['Mycophenolate mofetil'] @entity3621 :: ('MESH:D005756', 'Disease') :: ['gastritis'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity1140 :: ('MESH:D016559', 'Chemical') :: ['tacrolimus'] @entity9317 :: ('MESH:D004382', 'Disease') :: ['duodenitis']
@entity618 :: (MESH:C063008,Chemical) :: ['mycophenolate mofetil']
